CSPI Litigation Again Targets Bayer One A Day Claims
This article was originally published in The Tan Sheet
The proposed class-action complaint CSPI filed federal court marks the consumer advocacy group’s third allegation against claims for One A Day products. The complaint seeks an injunction against some claims and refunds to consumers who “purchased the products expecting the promised benefits,” CSPI says.
You may also be interested in...
On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.
The Center for Science in the Public Interest threatens to sue if Bayer HealthCare does not discontinue claims that One A Day multivitamins “support” breast, heart, eye and bone health. CSPI argues the problem is rooted in linking legitimate claims to scientific research in a way that implies disease claims.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.